TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Intravenous Lidocaine on Transperitoneal Laparoscopic Urological Surgery: A Prospective, Randomised, Placebo Controlled, Double-blind, Phase III Study
Brief Summary: Effective perioperative analgesia is the key to postoperative rehabilitation. An intriguing body of evidence suggests that short-term administration of intravenous lidocaine may produce pain relief that far exceeds both the duration of infusion and the half-life of the drug. When pain relief is provided, concomitant anal-gesic medication can be reduced, side effects from pain relieving medication minimized with a potential for a more rapid postoperative recovery and less complications. IV application of lidocaine should de-crease the duration of bowel dysfunction. We hypothesise that i.v. application of lidocaine in a standard antiarrythmic dose can significantly improve acute rehabilitation after laparoscopic urological surgery and so shorten the hospital stay (primary outcome). We expect that the intraoperative inflammatory response can significantly be reduced.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: lidocaine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupivacaine with hydromorphone | Intervention Type: DRUG; Name: bupivacaine with hydromorphone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: lidocaine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lidocaine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine Intravenous Infusion | Intervention Type: DRUG; Name: Lidocaine Intravenous Infusion; Assigned to Arm(s): Lidocaine
D: Arm Label: Intravenous lidocaine injection group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous lidocaine injection | Arm Label: Intraperitoneal lidocaine irrigation group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intraperitoneal lidocaine irrigation group | Arm Label: Intravenous normal saline group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous normal saline injection | Intervention Type: DRUG; Name: Intravenous lidocaine injection; Assigned to Arm(s): Intravenous lidocaine injection group | Intervention Type: DRUG; Name: Intraperitoneal lidocaine irrigation group; Assigned to Arm(s): Intraperitoneal lidocaine irrigation group | Intervention Type: DRUG; Name: Intravenous normal saline injection; Assigned to Arm(s): Intravenous normal saline group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Brief Summary: The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.


Options:
A: Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): N/A
B: Arm Label: GSK1120212 plus Gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: GSK1120212, Drug: Gemcitabine | Arm Label: Placebo plus Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: GSK1120212; Assigned to Arm(s): GSK1120212 plus Gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): GSK1120212 plus Gemcitabine, Placebo plus Gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Gemcitabine
C: Arm Label: Capecitabine and ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Drug: Ruxolitinib | Arm Label: Capecitabine and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine and placebo, Capecitabine and ruxolitinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Capecitabine and ruxolitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Capecitabine and placebo
D: Arm Label: Masitinib & gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Masitinib, Drug: Gemcitabine | Arm Label: Placebo & gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Gemcitabine | Intervention Type: DRUG; Name: Masitinib; Assigned to Arm(s): Masitinib & gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo & gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Masitinib & gemcitabine, Placebo & gemcitabine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)
Brief Summary: This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.


Options:
A: Arm Label: Everolimus (RAD001); Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus (RAD001)
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)
Brief Summary: This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.


Options:
A: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A
B: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm
C: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression
Brief Summary: The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an selective serotonin reuptake inhibitor or Venlafaxine versus Quetiapine extended release monotherapy in subjects with treatment resistant depression as assessed by the changes from randomisation to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. As an independent objective, the primary objective will also be evaluated in two subgroups of patients: (1) patients who were resistant to two previous antidepressant therapies and (2) in the subgroup of patients with one previous failure.


Options:
A: Arm Label: Add-on Quetiapine XR+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR, Drug: SSRI/Venlafaxine | Arm Label: Add-on Lithium+SSRI/Venlafaxine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium carbonate, Drug: SSRI/Venlafaxine | Arm Label: Monotherapy Quetiapine XR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine XR | Intervention Type: DRUG; Name: Quetiapine XR; Assigned to Arm(s): Add-on Quetiapine XR+SSRI/Venlafaxine, Monotherapy Quetiapine XR | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine | Intervention Type: DRUG; Name: SSRI/Venlafaxine; Assigned to Arm(s): Add-on Lithium+SSRI/Venlafaxine, Add-on Quetiapine XR+SSRI/Venlafaxine
B: Arm Label: Vortioxetine 10 mg or 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Agomelatine 25 mg or 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Agomelatine | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg or 20 mg | Intervention Type: DRUG; Name: Agomelatine; Assigned to Arm(s): Agomelatine 25 mg or 50 mg
C: Arm Label: Vilazodone 10mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 20mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Vilazodone 40mg; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 10mg, Vilazodone 20mg, Vilazodone 40mg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1-2 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 2-4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1-2 mg, Cariprazine 2-4.5 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery
Brief Summary: This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.


Options:
A: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
C: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
D: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery
Brief Summary: This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.


Options:
A: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
B: Arm Label: Carbetocin 10mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 20mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 40mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 60mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 80mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 120mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Carbetocin 140mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin 100mcg, Carbetocin 10mcg, Carbetocin 120mcg, Carbetocin 140mcg, Carbetocin 20mcg, Carbetocin 40mcg, Carbetocin 60mcg, Carbetocin 80mcg
C: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Effectiveness of 3 Different Dose Regimens of Oxytocin in Preventing Uterine Atony and Postpartum Hemorrhage During Vaginal Delivery
Brief Summary: This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.


Options:
A: Arm Label: Carbetocin; Type: N/A; Interventions: N/A | Arm Label: Oxytocin; Type: N/A; Interventions: N/A
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
C: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc
D: Arm Label: Arm A: sublingual misoprostol 600µg; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Arm B: 10 IU Oxytocin; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Arm A: sublingual misoprostol 600µg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial
Brief Summary: The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
C: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA | Arm Label: group 2; Type: EXPERIMENTAL; Interventions: Drug: rt-PA | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): group 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial
Brief Summary: The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
C: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS
D: Intervention Type: DEVICE; Name: Elastic stockings; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial
Brief Summary: The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.


Options:
A: Arm Label: LMWH; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparine calcium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: nadroparine calcium; Assigned to Arm(s): LMWH | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
C: Arm Label: Conventional anticoagulation therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Ekos Endowave system thrombolysis; Type: EXPERIMENTAL; Interventions: Device: Ekos endowave system thrombolysis | Intervention Type: DEVICE; Name: Ekos endowave system thrombolysis; Assigned to Arm(s): Ekos Endowave system thrombolysis
D: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group

Answer: B